Sci-Tech Europe: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Europe.

Press releases published on April 17, 2026

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
SplashBI Recognized as a Star Performer in Everest Group’s People Analytics Platforms PEAK Matrix® Assessment 2026
Introspect Technology Adds New ATE-on-Bench Solution for LPDDR6, DDR6, and HBM Interfaces
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
PRAME-directed Cell Therapy Using Immatics’ TCR  Induces Deep and Durable Remission in Pediatric Patient  with Advanced Metastatic Nephroblastoma
Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026
New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma
Pheast Therapeutics Reports Initial Phase 1a Data Showing Early Clinical Activity and Target Engagement for PHST001 at AACR 2026
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting
MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer
Can You Trust AI Therapy? New Report Exposes the Potential Risks of General AI for Mental Health
SINOVO Highlights Cost-Efficiency of Percussion Hammers Amid Alloy Price Volatility
AGM Mobile to Showcase Latest Rugged Innovations at Canton Fair 2026
Verum Messenger Introduces Major Platform Update Expanding Privacy, Connectivity, and Digital Ecosystem

Share this page:

Sign up for:

Sci-Tech Europe

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.